Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Second-generation long-acting injectable antipsychotic agents: an overview.

[No authors listed]

Drug Ther Bull. 2012 Sep;50(9):102-5. doi: 10.1136/dtb.2012.08.0127. Review.

PMID:
22966099
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.

[Guidelines for the use of second-generation long-acting antipsychotics].

Jarema M, Wichniak A, Dudek D, Samochowiec J, Bieńkowski P, Rybakowski J.

Psychiatr Pol. 2015 Mar-Apr;49(2):225-41. doi: 10.12740/PP/39370. Polish.

PMID:
26093588
4.

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.

Laux G, Heeg B, van Hout BA, Mehnert A.

Pharmacoeconomics. 2005;23 Suppl 1:49-61.

PMID:
16416761
5.

Efficacy and safety of long acting injectable atypical antipsychotics: a review.

De Berardis D, Marini S, Carano A, Lang AP, Cavuto M, Piersanti M, Fornaro M, Perna G, Valchera A, Mazza M, Iasevoli F, Martinotti G, Di Giannantonio M.

Curr Clin Pharmacol. 2013 Aug;8(3):256-64. Review.

PMID:
23343445
6.

Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.

Tempest M, Sapin C, Beillat M, Robinson P, Treur M.

J Ment Health Policy Econ. 2015 Dec;18(4):185-200.

PMID:
26729007
7.

Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic.

Einarson TR, Zilbershtein R, Skoupá J, Veselá S, Garg M, Hemels ME.

J Med Econ. 2013 Sep;16(9):1089-95. doi: 10.3111/13696998.2013.820193. Epub 2013 Jul 9.

PMID:
23808900
8.
9.

Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.

Mehnert A, Nicholl D, Pudas H, Martin M, McGuire A.

J Med Econ. 2012;15(5):844-61. doi: 10.3111/13696998.2012.681531. Epub 2012 Apr 26.

PMID:
22458756
10.

Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.

Druais S, Doutriaux A, Cognet M, Godet A, Lançon C, Levy P, Samalin L, Guillon P.

Pharmacoeconomics. 2016 Apr;34(4):363-91. doi: 10.1007/s40273-015-0348-x.

PMID:
26883132
11.

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.

De Graeve D, Smet A, Mehnert A, Caleo S, Miadi-Fargier H, Mosqueda GJ, Lecompte D, Peuskens J.

Pharmacoeconomics. 2005;23 Suppl 1:35-47.

PMID:
16416760
12.

In brief: Injectable paliperidone palmitate for schizophrenia.

[No authors listed]

Med Lett Drugs Ther. 2009 Nov 2;51(1324):88. No abstract available.

PMID:
19890247
13.

Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.

Park EJ, Amatya S, Kim MS, Park JH, Seol E, Lee H, Shin YH, Na DH.

Arch Pharm Res. 2013 Jun;36(6):651-9. doi: 10.1007/s12272-013-0105-7. Epub 2013 Apr 1. Review.

PMID:
23543652
14.

Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.

Einarson TR, Vicente C, Zilbershtein R, Piwko C, Bø CN, Pudas H, Jensen R, Hemels ME.

Nord J Psychiatry. 2014 Aug;68(6):416-27. doi: 10.3109/08039488.2013.852243. Epub 2013 Nov 25.

PMID:
24274837
15.

[Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].

Graffino M, Montemagni C, Mingrone C, Rocca P.

Riv Psichiatr. 2014 May-Jun;49(3):115-23. doi: 10.1708/1551.16905. Review. Italian.

PMID:
25000887
16.

Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.

Einarson TR, Maia-Lopes S, Goswami P, Bereza BG, Van Impe K.

J Med Econ. 2016 Sep;19(9):913-21. doi: 10.1080/13696998.2016.1184156. Epub 2016 May 13.

PMID:
27124697
17.

Cost effectiveness of paliperidone palmitate for the treatment of schizophrenia in Germany.

Zeidler J, Mahlich J, Greiner W, Heres S.

Appl Health Econ Health Policy. 2013 Oct;11(5):509-21. doi: 10.1007/s40258-013-0050-0. Erratum in: Appl Health Econ Health Policy. 2013 Dec;11(6):689.

PMID:
23975630
18.

Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.

Keith S.

Expert Rev Neurother. 2009 Jan;9(1):9-31. doi: 10.1586/14737175.9.1.9. Review.

PMID:
19102665
19.

Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.

Yang YK, Tarn YH, Wang TY, Liu CY, Laio YC, Chou YH, Lee SM, Chen CC.

Psychiatry Clin Neurosci. 2005 Aug;59(4):385-94. Erratum in: Psychiatry Clin Neurosci. 2005 Oct;59(5):625-6. Tarn, Yeng Hui [corrected to Tarn, Yen-Huei].

PMID:
16048443
20.

Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.

Cañas F, Möller HJ.

Expert Opin Drug Saf. 2010 Sep;9(5):683-97. doi: 10.1517/14740338.2010.506712. Review. Erratum in: Expert Opin Drug Saf. 2010 Nov;9(6):1007.

PMID:
20690885

Supplemental Content

Support Center